Montanova Capital LLC Purchases 16,142 Shares of Boston Scientific Corporation $BSX

Montanova Capital LLC increased its position in Boston Scientific Corporation (NYSE:BSX) by 13.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 140,083 shares of the medical equipment provider’s stock after acquiring an additional 16,142 shares during the quarter. Montanova Capital LLC’s holdings in Boston Scientific were worth $5,979,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. CYBER HORNET ETFs LLC increased its stake in shares of Boston Scientific by 3.4% in the third quarter. CYBER HORNET ETFs LLC now owns 4,004 shares of the medical equipment provider’s stock worth $391,000 after purchasing an additional 132 shares during the period. Gerber Kawasaki Wealth & Investment Management boosted its stake in Boston Scientific by 4.7% during the 4th quarter. Gerber Kawasaki Wealth & Investment Management now owns 3,082 shares of the medical equipment provider’s stock valued at $294,000 after purchasing an additional 139 shares during the period. Northwestern Mutual Investment Management Company LLC boosted its stake in Boston Scientific by 0.3% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 47,366 shares of the medical equipment provider’s stock valued at $4,516,000 after purchasing an additional 140 shares during the period. Kingsview Wealth Management LLC grew its holdings in Boston Scientific by 2.4% in the 4th quarter. Kingsview Wealth Management LLC now owns 6,066 shares of the medical equipment provider’s stock valued at $578,000 after buying an additional 142 shares during the last quarter. Finally, Fairfield Financial Advisors LTD grew its holdings in Boston Scientific by 2.9% in the 4th quarter. Fairfield Financial Advisors LTD now owns 5,366 shares of the medical equipment provider’s stock valued at $512,000 after buying an additional 150 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $60.00 price target on shares of Boston Scientific in a report on Thursday, July 30th. Raymond James Financial reaffirmed an “outperform” rating and set a $57.00 target price on shares of Boston Scientific in a research report on Thursday, July 30th. Needham & Company LLC cut their target price on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating for the company in a research note on Wednesday, July 8th. Oppenheimer reduced their price target on shares of Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a report on Monday, July 27th. Finally, Evercore set a $65.00 price target on shares of Boston Scientific in a research report on Monday, July 6th. Twenty-four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $71.62.

Insiders Place Their Bets

In related news, Director Edward J. Ludwig acquired 5,000 shares of the firm’s stock in a transaction on Friday, July 31st. The shares were bought at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the acquisition, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Michael F. Mahoney acquired 186,240 shares of the stock in a transaction dated Monday, August 3rd. The stock was bought at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 194,522 shares of company stock worth $9,385,210 over the last quarter. Company insiders own 0.34% of the company’s stock.

Boston Scientific Stock Up 3.2%

Shares of BSX stock opened at $48.35 on Tuesday. The stock has a market cap of $70.07 billion, a P/E ratio of 19.57, a price-to-earnings-growth ratio of 1.02 and a beta of 0.56. Boston Scientific Corporation has a one year low of $42.20 and a one year high of $109.50. The stock has a fifty day moving average price of $46.65 and a 200 day moving average price of $56.35. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its board has initiated a stock repurchase program on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board of directors believes its stock is undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.